A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

  • Infectious Diseases
  • COVID-19 Pneumonia
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:

Completed

This study runs in
Cities
  • Barcelona
  • Baton Rouge
  • Breda
  • Chicago
  • Cleveland
  • Denver
  • Durham
  • Düsseldorf
  • Glasgow
  • Hackensack
  • Hamilton
  • Hannover
  • Houston
  • Hvidovre
  • Kirkland
  • Köln
  • København
  • L'Hospitalet de Llobregat
  • La Jolla
  • La Roche-sur-Yon
  • Leeds
  • Limoges
  • London
  • Los Angeles
  • Lyon
  • Madrid
  • Manchester
  • Miami
  • Montréal
  • Monza
  • München
  • Nantes
  • New Brunswick
  • New York
  • Nieuwegein
  • Odense
  • Paris
  • Pavia
  • Philadelphia
  • Rochester
  • Roskilde
  • Rotterdam
  • Salt Lake City
  • San Diego
  • Seattle
  • Springfield
  • St. George
  • Stanford
  • Toronto
  • Tours
  • Utrecht
Trial Identifier:

NCT04320615 2020-001154-22 WA42380

      Show study locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Study Summary

      This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics of tocilizumab (TCZ) compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with severe COVID-19 pneumonia.

      Hoffmann-La Roche Sponsor
      Phase 3 Phase
      NCT04320615, WA42380, 2020-001154-22 Trial Identifier
      Tocilizumab (TCZ), Placebo Treatments
      COVID-19 Pneumonia Condition
      Official Title

      A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Studies

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      COVID-19 Pneumonia

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now